Pharvaris (NASDAQ:PHVS) NV is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel therapies for rare, bradykinin‐mediated diseases. The company’s primary focus is hereditary angioedema (HAE), a genetic condition characterized by recurrent, debilitating swelling episodes. Pharvaris leverages a small‐molecule approach targeting the bradykinin B2 receptor, aiming to provide both prophylactic and on‐demand treatment options that improve upon current injectable therapies.
The company’s lead product candidate, PHA121, is an oral, selective bradykinin B2 receptor antagonist currently in Phase 1 clinical trials. Preclinical data have demonstrated favorable pharmacokinetics, strong receptor occupancy and a safety profile supporting further development. In addition to PHA121, Pharvaris is advancing a pipeline of next‐generation molecules designed to address unmet needs in HAE and potentially other bradykinin‐driven conditions, with plans to initiate additional clinical studies in the near term.
Founded in 2017 as a spin‐out from academic research, Pharvaris has grown rapidly to assemble a team experienced in rare disease drug development. The company’s scientific founders brought deep expertise in vascular biology and peptide chemistry, while its operational leaders have held senior roles at leading pharmaceutical firms and biotech companies. This blend of academic rigor and industry know‐how underpins Pharvaris’s approach to translating novel science into patient‐focused therapies.
Headquartered in Cambridge, Massachusetts, and with a research facility in Belgium, Pharvaris serves global markets and aims to address the needs of HAE patients in North America, Europe and beyond. The company is led by CEO Jonathan Bangs, whose prior experience includes leadership roles at both emerging biotech firms and large pharmaceutical organizations, and is supported by a board and management team with decades of combined expertise in drug discovery, clinical development and commercial strategy.
